Ferroptosis-induced Cardiotoxicity and Antitumor Drugs

Curigliano, G.; Lenihan, D.; Fradley, M.; Ganatra, S.; Barac, A.; Blaes, A.; Herrmann, J.; Porter, C.; Lyon, A.R.; Lancellotti, P.; Patel, A.; DeCara, J.; Mitchell, J.; Harrison, E.; Moslehi, J.; Witteles, R.; Calabro, M.G.; Orecchia, R.; de Azambuja, E.; Zamorano, J.L.; Krone, R.; Iakobishvili, Z.; Carver, J.; Armenian, S.; Ky, B.; Cardinale, D.; Cipolla, C.M.; Dent, S.; Jordan, K. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol., 2020, 31(2), 171-190.
[http://dx.doi.org/10.1016/j.annonc.2019.10.023] [PMID: 31959335]

Zamorano, J.L.; Lancellotti, P.; Rodriguez Muñoz, D.; Aboyans, V.; Asteggiano, R.; Galderisi, M.; Habib, G.; Lenihan, D.J.; Lip, G.Y.H.; Lyon, A.R.; Lopez Fernandez, T.; Mohty, D.; Piepoli, M.F.; Tamargo, J.; Torbicki, A.; Suter, T.M. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J., 2016, 37(36), 2768-2801.
[http://dx.doi.org/10.1093/eurheartj/ehw211] [PMID: 27567406]

Cardinale, D.; Colombo, A.; Lamantia, G.; Colombo, N.; Civelli, M.; De Giacomi, G.; Pandini, C.; Sandri, M.T.; Cipolla, C.M. Cardio-oncology: A new medical issue. Ecancermedicalscience, 2009, 3, 126.
[http://dx.doi.org/10.3332/ecancer.2008.126] [PMID: 22275992]

Galluzzi, L.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Agostinis, P.; Alnemri, E.S.; Altucci, L.; Amelio, I.; Andrews, D.W.; Annicchiarico-Petruzzelli, M.; Antonov, A.V.; Arama, E.; Baehrecke, E.H.; Barlev, N.A.; Bazan, N.G.; Bernassola, F.; Bertrand, M.J.M.; Bianchi, K.; Blagosklonny, M.V.; Blomgren, K.; Borner, C.; Boya, P.; Brenner, C.; Campanella, M.; Candi, E.; Carmona-Gutierrez, D.; Cecconi, F.; Chan, F.K.M.; Chandel, N.S.; Cheng, E.H.; Chipuk, J.E.; Cidlowski, J.A.; Ciechanover, A.; Cohen, G.M.; Conrad, M.; Cubillos-Ruiz, J.R.; Czabotar, P.E.; D’Angiolella, V.; Dawson, T.M.; Dawson, V.L.; De Laurenzi, V.; De Maria, R.; Debatin, K.M.; DeBerardinis, R.J.; Deshmukh, M.; Di Daniele, N.; Di Virgilio, F.; Dixit, V.M.; Dixon, S.J.; Duckett, C.S.; Dynlacht, B.D.; El-Deiry, W.S.; Elrod, J.W.; Fimia, G.M.; Fulda, S.; García-Sáez, A.J.; Garg, A.D.; Garrido, C.; Gavathiotis, E.; Golstein, P.; Gottlieb, E.; Green, D.R.; Greene, L.A.; Gronemeyer, H.; Gross, A.; Hajnoczky, G.; Hardwick, J.M.; Harris, I.S.; Hengartner, M.O.; Hetz, C.; Ichijo, H.; Jäättelä, M.; Joseph, B.; Jost, P.J.; Juin, P.P.; Kaiser, W.J.; Karin, M.; Kaufmann, T.; Kepp, O.; Kimchi, A.; Kitsis, R.N.; Klionsky, D.J.; Knight, R.A.; Kumar, S.; Lee, S.W.; Lemasters, J.J.; Levine, B.; Linkermann, A.; Lipton, S.A.; Lockshin, R.A.; López-Otín, C.; Lowe, S.W.; Luedde, T.; Lugli, E.; MacFarlane, M.; Madeo, F.; Malewicz, M.; Malorni, W.; Manic, G.; Marine, J.C.; Martin, S.J.; Martinou, J.C.; Medema, J.P.; Mehlen, P.; Meier, P.; Melino, S.; Miao, E.A.; Molkentin, J.D.; Moll, U.M.; Muñoz-Pinedo, C.; Nagata, S.; Nuñez, G.; Oberst, A.; Oren, M.; Overholtzer, M.; Pagano, M.; Panaretakis, T.; Pasparakis, M.; Penninger, J.M.; Pereira, D.M.; Pervaiz, S.; Peter, M.E.; Piacentini, M.; Pinton, P.; Prehn, J.H.M.; Puthalakath, H.; Rabinovich, G.A.; Rehm, M.; Rizzuto, R.; Rodrigues, C.M.P.; Rubinsztein, D.C.; Rudel, T.; Ryan, K.M.; Sayan, E.; Scorrano, L.; Shao, F.; Shi, Y.; Silke, J.; Simon, H.U.; Sistigu, A.; Stockwell, B.R.; Strasser, A.; Szabadkai, G.; Tait, S.W.G.; Tang, D.; Tavernarakis, N.; Thorburn, A.; Tsujimoto, Y.; Turk, B.; Vanden Berghe, T.; Vandenabeele, P.; Vander Heiden, M.G.; Villunger, A.; Virgin, H.W.; Vousden, K.H.; Vucic, D.; Wagner, E.F.; Walczak, H.; Wallach, D.; Wang, Y.; Wells, J.A.; Wood, W.; Yuan, J.; Zakeri, Z.; Zhivotovsky, B.; Zitvogel, L.; Melino, G.; Kroemer, G. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ., 2018, 25(3), 486-541.
[http://dx.doi.org/10.1038/s41418-017-0012-4] [PMID: 29362479]

Tang, D.; Kang, R.; Berghe, T.V.; Vandenabeele, P.; Kroemer, G. The molecular machinery of regulated cell death. Cell Res., 2019, 29(5), 347-364.
[http://dx.doi.org/10.1038/s41422-019-0164-5] [PMID: 30948788]

Pandey, S.S.; Singh, S.; Pathak, C.; Tiwari, B.S. “Programmed cell death: A process of death for survival” – How far terminology pertinent for cell death in unicellular organisms. J. Cell Death, 2018, 11
[http://dx.doi.org/10.1177/1179066018790259] [PMID: 30116103]

Mishra, P.K.; Adameova, A.; Hill, J.A.; Baines, C.P.; Kang, P.M.; Downey, J.M.; Narula, J.; Takahashi, M.; Abbate, A.; Piristine, H.C.; Kar, S.; Su, S.; Higa, J.K.; Kawasaki, N.K.; Matsui, T. Guidelines for evaluating myocardial cell death. Am. J. Physiol. Heart Circ. Physiol., 2019, 317(5), H891-H922.
[http://dx.doi.org/10.1152/ajpheart.00259.2019] [PMID: 31418596]

Baker, L.H.; Boonstra, P.S.; Reinke, D.K.; Antalis, E.J.P.; Zebrack, B.J.; Weinberg, R.L. Burden of chronic diseases among sarcoma survivors treated with anthracycline chemotherapy: results from an observational study. J Cancer Metastasis Treat., 2020, 6, 24.
[http://dx.doi.org/10.20517/2394-4722.2020.36]

Lei, G.; Zhuang, L.; Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer, 2022, 22(7), 381-396.
[http://dx.doi.org/10.1038/s41568-022-00459-0] [PMID: 35338310]

Friedmann Angeli, J.P.; Krysko, D.V.; Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer, 2019, 19(7), 405-414.
[http://dx.doi.org/10.1038/s41568-019-0149-1] [PMID: 31101865]

Torti, S.V.; Torti, F.M. Winning the war with iron. Nat. Nanotechnol., 2019, 14(6), 499-500.
[http://dx.doi.org/10.1038/s41565-019-0419-9] [PMID: 30911165]

Fang, X.; Ardehali, H.; Min, J.; Wang, F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat. Rev. Cardiol., 2023, 20(1), 7-23.
[http://dx.doi.org/10.1038/s41569-022-00735-4] [PMID: 35788564]

Komai, K.; Kawasaki, N.K.; Higa, J.K.; Matsui, T. The role of ferroptosis in adverse left ventricular remodeling following acute myocardial infarction. Cells, 2022, 11(9), 1399.
[http://dx.doi.org/10.3390/cells11091399] [PMID: 35563704]

Herrmann, J.; Lenihan, D.; Armenian, S.; Barac, A.; Blaes, A.; Cardinale, D.; Carver, J.; Dent, S.; Ky, B.; Lyon, A.R.; López-Fernández, T.; Fradley, M.G.; Ganatra, S.; Curigliano, G.; Mitchell, J.D.; Minotti, G.; Lang, N.N.; Liu, J.E.; Neilan, T.G.; Nohria, A.; O’Quinn, R.; Pusic, I.; Porter, C.; Reynolds, K.L.; Ruddy, K.J.; Thavendiranathan, P.; Valent, P. Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement. Eur. Heart J., 2022, 43(4), 280-299.
[http://dx.doi.org/10.1093/eurheartj/ehab674] [PMID: 34904661]

Dent, S.F.; Kikuchi, R.; Kondapalli, L.; Ismail-Khan, R.; Brezden-Masley, C.; Barac, A.; Fradley, M. Optimizing cardiovascular health in patients with cancer: A practical review of risk assessment, monitoring, and prevention of cancer treatment–related cardiovascular toxicity. Am. Soc. Clin. Oncol. Educ. Book, 2020, 40(40), 501-515.
[http://dx.doi.org/10.1200/EDBK_286019] [PMID: 32213102]

Dixon, S.J.; Lemberg, K.M.; Lamprecht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; Morrison, B., III; Stockwell, B.R. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell, 2012, 149(5), 1060-1072.
[http://dx.doi.org/10.1016/j.cell.2012.03.042] [PMID: 22632970]

Berghe, T.V.; Vanlangenakker, N.; Parthoens, E.; Deckers, W.; Devos, M.; Festjens, N.; Guerin, C.J.; Brunk, U.T.; Declercq, W.; Vandenabeele, P. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ., 2010, 17(6), 922-930.
[http://dx.doi.org/10.1038/cdd.2009.184] [PMID: 20010783]

Lei, P.; Bai, T.; Sun, Y. Mechanisms of ferroptosis and relations with regulated cell death: A review. Front. Physiol., 2019, 10, 139.
[http://dx.doi.org/10.3389/fphys.2019.00139] [PMID: 30863316]

Liang, C.; Zhang, X.; Yang, M.; Dong, X. Recent progress in ferroptosis inducers for cancer therapy. Adv. Mater., 2019, 31(51), 1904197.
[http://dx.doi.org/10.1002/adma.201904197] [PMID: 31595562]

Trujillo-Alonso, V.; Pratt, E.C.; Zong, H.; Lara-Martinez, A.; Kaittanis, C.; Rabie, M.O.; Longo, V.; Becker, M.W.; Roboz, G.J.; Grimm, J.; Guzman, M.L. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat. Nanotechnol., 2019, 14(6), 616-622.
[http://dx.doi.org/10.1038/s41565-019-0406-1] [PMID: 30911166]

Tang, M.; Chen, Z.; Wu, D.; Chen, L. Ferritinophagy/ferroptosis: Iron-related newcomers in human diseases. J. Cell. Physiol., 2018, 233(12), 9179-9190.
[http://dx.doi.org/10.1002/jcp.26954] [PMID: 30076709]

Mancias, J.D.; Wang, X.; Gygi, S.P.; Harper, J.W.; Kimmelman, A.C. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature, 2014, 509(7498), 105-109.
[http://dx.doi.org/10.1038/nature13148] [PMID: 24695223]

Yang, W.S.; Stockwell, B.R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol., 2008, 15(3), 234-245.
[http://dx.doi.org/10.1016/j.chembiol.2008.02.010] [PMID: 18355723]

Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.I.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascón, S.; Hatzios, S.K.; Kagan, V.E.; Noel, K.; Jiang, X.; Linkermann, A.; Murphy, M.E.; Overholtzer, M.; Oyagi, A.; Pagnussat, G.C.; Park, J.; Ran, Q.; Rosenfeld, C.S.; Salnikow, K.; Tang, D.; Torti, F.M.; Torti, S.V.; Toyokuni, S.; Woerpel, K.A.; Zhang, D.D. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 2017, 171(2), 273-285.
[http://dx.doi.org/10.1016/j.cell.2017.09.021] [PMID: 28985560]

Doll, S.; Conrad, M. Iron and ferroptosis: A still ill-defined liaison. IUBMB Life, 2017, 69(6), 423-434.
[http://dx.doi.org/10.1002/iub.1616] [PMID: 28276141]

Jennis, M.; Kung, C.P.; Basu, S.; Budina-Kolomets, A.; Leu, J.I.J.; Khaku, S.; Scott, J.P.; Cai, K.Q.; Campbell, M.R.; Porter, D.K.; Wang, X.; Bell, D.A.; Li, X.; Garlick, D.S.; Liu, Q.; Hollstein, M.; George, D.L.; Murphy, M.E. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev., 2016, 30(8), 918-930.
[http://dx.doi.org/10.1101/gad.275891.115] [PMID: 27034505]

Jiang, L.; Kon, N.; Li, T.; Wang, S.J.; Su, T.; Hibshoosh, H.; Baer, R.; Gu, W. Ferroptosis as a p53-mediated activity during tumour suppression. Nature, 2015, 520(7545), 57-62.
[http://dx.doi.org/10.1038/nature14344] [PMID: 25799988]

Zhang, Y.; Shi, J.; Liu, X.; Feng, L.; Gong, Z.; Koppula, P.; Sirohi, K.; Li, X.; Wei, Y.; Lee, H.; Zhuang, L.; Chen, G.; Xiao, Z.D.; Hung, M.C.; Chen, J.; Huang, P.; Li, W.; Gan, B. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol., 2018, 20(10), 1181-1192.
[http://dx.doi.org/10.1038/s41556-018-0178-0] [PMID: 30202049]

Ou, Y.; Wang, S.J.; Li, D.; Chu, B.; Gu, W. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc. Natl. Acad. Sci., 2016, 113(44), E6806-E6812.
[http://dx.doi.org/10.1073/pnas.1607152113] [PMID: 27698118]

Shah, R.; Margison, K.; Pratt, D.A. The potency of diarylamine radical-trapping antioxidants as inhibitors of ferroptosis underscores the role of autoxidation in the mechanism of cell death. ACS Chem. Biol., 2017, 12(10), 2538-2545.
[http://dx.doi.org/10.1021/acschembio.7b00730] [PMID: 28837769]

D’Herde, K.; Krysko, D.V. Oxidized PEs trigger death. Nat. Chem. Biol., 2017, 13(1), 4-5.
[http://dx.doi.org/10.1038/nchembio.2261] [PMID: 27842067]

Lin, L.S.; Song, J.; Song, L.; Ke, K.; Liu, Y.; Zhou, Z.; Shen, Z.; Li, J.; Yang, Z.; Tang, W.; Niu, G.; Yang, H.H.; Chen, X. Simultaneous fenton-like ion delivery and glutathione depletion by MnO₂ -based nanoagent to enhance chemodynamic therapy. Angew. Chem. Int. Ed., 2018, 57(18), 4902-4906.
[http://dx.doi.org/10.1002/anie.201712027] [PMID: 29488312]

Yang, W.S.; Kim, K.J.; Gaschler, M.M.; Patel, M.; Shchepinov, M.S.; Stockwell, B.R. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci., 2016, 113(34), E4966-E4975.
[http://dx.doi.org/10.1073/pnas.1603244113] [PMID: 27506793]

Yuan, H.; Li, X.; Zhang, X.; Kang, R.; Tang, D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun., 2016, 478(3), 1338-1343.
[http://dx.doi.org/10.1016/j.bbrc.2016.08.124] [PMID: 27565726]

Gaschler, M.M.; Stockwell, B.R. Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun., 2017, 482(3), 419-425.
[http://dx.doi.org/10.1016/j.bbrc.2016.10.086] [PMID: 28212725]

Feng, H.; Stockwell, B.R. Unsolved mysteries: How does lipid peroxidation cause ferroptosis? PLoS Biol., 2018, 16(5), e2006203.
[http://dx.doi.org/10.1371/journal.pbio.2006203] [PMID: 29795546]

Wenzel, S.E.; Tyurina, Y.Y.; Zhao, J.; St Croix, C.M.; Dar, H.H.; Mao, G.; Tyurin, V.A.; Anthonymuthu, T.S.; Kapralov, A.A.; Amoscato, A.A.; Mikulska-Ruminska, K.; Shrivastava, I.H.; Kenny, E.M.; Yang, Q.; Rosenbaum, J.C.; Sparvero, L.J.; Emlet, D.R.; Wen, X.; Minami, Y.; Qu, F.; Watkins, S.C.; Holman, T.R.; VanDemark, A.P.; Kellum, J.A.; Bahar, I.; Bayır, H.; Kagan, V.E. PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell, 2017, 171(3), 628-641.e26.
[http://dx.doi.org/10.1016/j.cell.2017.09.044] [PMID: 29053969]

Seibt, T.M.; Proneth, B.; Conrad, M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic. Biol. Med., 2019, 133, 144-152.
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.09.014] [PMID: 30219704]

Kryukov, G.V.; Castellano, S.; Novoselov, S.V.; Lobanov, A.V.; Zehtab, O.; Guigó, R.; Gladyshev, V.N. Characterization of mammalian selenoproteomes. Science, 2003, 300(5624), 1439-1443.
[http://dx.doi.org/10.1126/science.1083516] [PMID: 12775843]

Doll, S.; Freitas, F.P.; Shah, R.; Aldrovandi, M.; da Silva, M.C.; Ingold, I.; Goya Grocin, A. FSP1 is a glutathione-independent ferroptosis suppressor. Nature, 2019, 575(7784), 693-698.
[http://dx.doi.org/10.1038/s41586-019-1707-0]

Bersuker, K.; Hendricks, J.M; Li, Z.; Magtanong, L.; Ford, B.; Tang, P.H.; Roberts, M.A.; Tong, B.; Maimone, T.J.; Zoncu, R.; Bassik, M.C.; Nomura, D.K. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature, 2019, 575(7784), 688-692.

Ma, W.; Wei, S.; Zhang, B.; Li, W. Molecular mechanisms of cardiomyocyte death in drug-induced cardiotoxicity. Front Cell Dev Biol., 2020, 8, 434.
[http://dx.doi.org/10.3389/fcell.2020.00434]

Narayan, V.; Ky, b.; Cerra, M.C.; Angelone, T. Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention. Annu Rev Med., 2018, 69(15), 97-111.

Rocca, C.; Pasqua, T.; Cerra, M.C.; Angelone, T. Cardiac damage in anthracyclines therapy: Focus on oxidative stress and inflammation. Antioxid. Redox Signal., 2020, 32(15), 1081-1097.
[http://dx.doi.org/10.1089/ars.2020.8016] [PMID: 31928066]

Kitakata, H.; Endo, J.; Ikura, H.; Moriyama, H.; Shirakawa, K.; Katsumata, Y.; Sano, M. Therapeutic targets for dox-induced cardiomyopathy: role of apoptosis vs. ferroptosis. Int. J. Mol. Sci., 2022, 23(3), 1414.
[http://dx.doi.org/10.3390/ijms23031414] [PMID: 35163335]

Vejpongsa, P.; Yeh, E.T.H. Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. J. Am. Coll. Cardiol., 2014, 64(9), 938-945.
[http://dx.doi.org/10.1016/j.jacc.2014.06.1167] [PMID: 25169180]

Wu, X.; Li, Y.; Zhang, S.; Zhou, X. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics, 2021, 11(7), 3052-3059.
[http://dx.doi.org/10.7150/thno.54113] [PMID: 33537073]

Zhai, Z.; Zou, P.; Liu, F.; Xia, Z.; Li, J. Ferroptosis is a potential novel diagnostic and therapeutic target for patients with cardiomyopathy. Front. Cell Dev. Biol., 2021, 9, 649045.
[http://dx.doi.org/10.3389/fcell.2021.649045] [PMID: 33869204]

Zhang, H.; Wang, Z.; Liu, Z.; Du, K.; Lu, X. Protective effects of dexazoxane on rat ferroptosis in doxorubicin-induced cardiomyopathy through regulating HMGB1. Front. Cardiovasc. Med., 2021, 8, 685434.
[http://dx.doi.org/10.3389/fcvm.2021.685434] [PMID: 34336950]

Fang, X.; Wang, H.; Han, D.; Xie, E.; Yang, X.; Wei, J.; Gu, S.; Gao, F.; Zhu, N.; Yin, X.; Cheng, Q.; Zhang, P.; Dai, W.; Chen, J.; Yang, F.; Yang, H.T.; Linkermann, A.; Gu, W.; Min, J.; Wang, F. Ferroptosis as a target for protection against cardiomyopathy. Proc. Natl. Acad. Sci., 2019, 116(7), 2672-2680.
[http://dx.doi.org/10.1073/pnas.1821022116] [PMID: 30692261]

Finn, N.A.; Findley, H.W.; Kemp, M.L. A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity. PLOS Comput. Biol., 2011, 7(9), e1002151.
[http://dx.doi.org/10.1371/journal.pcbi.1002151] [PMID: 21935349]

Lewandowski, M.; Gwozdzinski, K. Nitroxides as antioxidants and anticancer drugs. Int. J. Mol. Sci., 2017, 18(11), 2490.
[http://dx.doi.org/10.3390/ijms18112490] [PMID: 29165366]

Zhao, L.; Qi, Y.; Xu, L.; Tao, X.; Han, X.; Yin, L.; Peng, J. MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol., 2018, 15, 284-296.
[http://dx.doi.org/10.1016/j.redox.2017.12.013] [PMID: 29304479]

Sunitha, M.C.; Dhanyakrishnan, R.; PrakashKumar, B.; Nevin, K.G. p-Coumaric acid mediated protection of H9c2 cells from Doxorubicin-induced cardiotoxicity: Involvement of augmented Nrf2 and autophagy. Biomed. Pharmacother., 2018, 102, 823-832.
[http://dx.doi.org/10.1016/j.biopha.2018.03.089] [PMID: 29605770]

He, L.; Yang, Y.; Chen, J.; Zou, P.; Li, J. Transcriptional activation of ENPP2 by FoxO4 protects cardiomyocytes from doxorubicin-induced toxicity. Mol. Med. Rep., 2021, 24(3), 668.
[http://dx.doi.org/10.3892/mmr.2021.12307] [PMID: 34296293]

Mordente, A.; Meucci, E.; Silvestrini, A.; Martorana, G.; Giardina, B. New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem., 2009, 16(13), 1656-1672.
[http://dx.doi.org/10.2174/092986709788186228] [PMID: 19442138]

Stewart, D.J.; Grewaal, D.; Green, R.M.; Mikhael, N.; Goel, R.; Montpetit, V.A.; Redmond, M.D. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res., 1993, 13(6A), 1945-1952.
[PMID: 8297100]

Xu, X.; Persson, H.L.; Richardson, D.R. Molecular pharmacology of the interaction of anthracyclines with iron. Mol. Pharmacol., 2005, 68(2), 261-271.
[http://dx.doi.org/10.1124/mol.105.013383] [PMID: 15883202]

Zhou, Y.J.; Duan, D.Q.; Lu, L.Q.; Tang, L.J.; Zhang, X.J.; Luo, X.J.; Peng, J. The SPATA2/CYLD pathway contributes to doxorubicin-induced cardiomyocyte ferroptosis via enhancing ferritinophagy. Chem. Biol. Interact., 2022, 368, 110205.
[http://dx.doi.org/10.1016/j.cbi.2022.110205] [PMID: 36195186]

Zhu, X.; Wang, X.; Zhu, B.; Ding, S.; Shi, H.; Yang, X. Disruption of histamine/H₁R-STAT3-SLC7A11 axis exacerbates doxorubicin-induced cardiac ferroptosis. Free Radic. Biol. Med., 2022, 192, 98-114.
[http://dx.doi.org/10.1016/j.freeradbiomed.2022.09.012] [PMID: 36165929]

Qian, J.; Wan, W.; Fan, M. HMOX1 silencing prevents doxorubicin-induced cardiomyocyte injury, mitochondrial dysfunction, and ferroptosis by downregulating CTGF. Gen. Thorac. Cardiovasc. Surg., 2022, 71(5), 280-290.
[http://dx.doi.org/10.1007/s11748-022-01867-7]

Li, X.; Liang, J.; Qu, L.; Liu, S.; Qin, A.; Liu, H.; Wang, T.; Li, W.; Zou, W. Exploring the role of ferroptosis in the doxorubicin-induced chronic cardiotoxicity using a murine model. Chem. Biol. Interact., 2022, 363, 110008.
[http://dx.doi.org/10.1016/j.cbi.2022.110008] [PMID: 35667395]

Wang, Y.; Yan, S.; Liu, X.; Deng, F.; Wang, P.; Yang, L.; Hu, L.; Huang, K.; He, J. PRMT4 promotes ferroptosis to aggravate doxorubicin-induced cardiomyopathy via inhibition of the Nrf2/GPX4 pathway. Cell Death Differ., 2022, 29(10), 1982-1995.
[http://dx.doi.org/10.1038/s41418-022-00990-5] [PMID: 35383293]

Hou, K.; Shen, J.; Yan, J.; Zhai, C.; Zhang, J.; Pan, J.A.; Zhang, Y.; Jiang, Y.; Wang, Y.; Lin, R.Z.; Cong, H.; Gao, S.; Zong, W.X. Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin. EBioMedicine, 2021, 69, 103456.
[http://dx.doi.org/10.1016/j.ebiom.2021.103456] [PMID: 34233258]

Liu, Y.; Zeng, L.; Yang, Y.; Chen, C.; Wang, D.; Wang, H. Acyl-CoA thioesterase 1 prevents cardiomyocytes from Doxorubicin-induced ferroptosis via shaping the lipid composition. Cell Death Dis., 2020, 11(9), 756.
[http://dx.doi.org/10.1038/s41419-020-02948-2] [PMID: 32934217]

Nemade, H.; Chaudhari, U.; Acharya, A.; Hescheler, J.; Hengstler, J.G.; Papadopoulos, S.; Sachinidis, A. Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol., 2018, 92(4), 1507-1524.
[http://dx.doi.org/10.1007/s00204-018-2170-7]

Li, Y.; Yan, J.; Zhao, Q.; Zhang, Y.; Zhang, Y. ATF3 promotes ferroptosis in sorafenib-induced cardiotoxicity by suppressing Slc7a11 expression. Front. Pharmacol., 2022, 13, 904314.
[http://dx.doi.org/10.3389/fphar.2022.904314] [PMID: 36210815]

Jiang, H.; Wang, C.; Zhang, A.; Li, Y.; Li, J.; Li, Z.; Yang, X.; Hou, Y. ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. Biomed. Pharmacother., 2022, 153, 113280.
[http://dx.doi.org/10.1016/j.biopha.2022.113280] [PMID: 35724508]

Zhang, S.; Xu, X.; Li, Z.; Yi, T.; Ma, J.; Zhang, Y.; Li, Y. Analysis and validation of differentially expressed ferroptosis-related genes in regorafenib-induced cardiotoxicity. Oxid. Med. Cell Longev., 2022, 2022, 2513263.
[http://dx.doi.org/10.1155/2022/2513263]

Song, C.; Li, D.; Zhang, J.; Zhao, X. Role of ferroptosis in promoting cardiotoxicity induced by Imatinib Mesylate via down-regulating Nrf2 pathways in vitro and in vivo. Toxicol. Appl. Pharmacol., 2022, 435, 115852.
[http://dx.doi.org/10.1016/j.taap.2021.115852]

Sun, L.; Wang, H.; Xu, D.; Yu, S.; Zhang, L.; Li, X. Lapatinib induces mitochondrial dysfunction to enhance oxidative stress and ferroptosis in doxorubicin-induced cardiomyocytes via inhibition of PI3K/AKT signaling pathway. Bioengineered., 2022, 13(1), 48-60.
[http://dx.doi.org/10.1080/21655979.2021.2004980]

Sun, L.; Wang, H.; Yu, S.; Zhang, L.; Jiang, J.; Zhou, Q. Herceptin induces ferroptosis and mitochondrial dysfunction in H9c2 cells. Int. J. Mol. Med., 2022, 49(2), 17.
[http://dx.doi.org/10.3892/ijmm.2021.5072]

Wang, L.; Liu, S.; Gao, C.; Chen, H.; Li, J.; Lu, J.; Yuan, Y.; Zheng, X.; He, H.; Zhang, X.; Zhang, R.; Zhang, Y.; Wu, Y.; Lin, W.; Zheng, H. Arsenic trioxide-induced cardiotoxicity triggers ferroptosis in cardiomyoblast cells. Hum. Exp. Toxicol., 2022, 41, 9603271211064537.
[http://dx.doi.org/10.1177/09603271211064537]

Li, D.; Song, C.; Zhang, J.; Zhao, X. ROS and iron homeostasis dependent ferroptosis play a vital role in 5-Fluorouracil induced cardiotoxicity in vitro and in vivo. Toxicology., 2022, 468, 153113.
[http://dx.doi.org/10.1016/j.tox.2022.153113]

Liu, X.; Chen, C.; Han, D.; Zhou, W.; Cui, Y.; Tang, X.; Xiao, C.; Wang, Y.; Gao, Y. SLC7A11/GPX4 inactivation-mediated ferroptosis contributes to the pathogenesis of triptolide-induced cardiotoxicity. Oxid. Med. Cell Longev., 2022, 2022, 3192607.
[http://dx.doi.org/10.1155/2022/3192607]

Li, X.R.; Cheng, X.H.; Zhang, G.N.; Wang, X.X.; Huang, J.M. Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer. J. Ovarian Res., 2022, 15(1), 96.
[http://dx.doi.org/10.1186/s13048-022-01029-6] [PMID: 35971131]

Chen, Y.; Shi, S.; Dai, Y. Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy. Biomed. Pharmacother., 2022, 156, 113903.
[http://dx.doi.org/10.1016/j.biopha.2022.113903] [PMID: 36279722]

Li, N.; Wang, W.; Zhou, H.; Wu, Q.; Duan, M.; Liu, C.; Wu, H.; Deng, W.; Shen, D.; Tang, Q. Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. Free Radic. Biol. Med., 2020, 160, 303-318.
[http://dx.doi.org/10.1016/j.freeradbiomed.2020.08.009]

Yang, K.T.; Chao, T.H.; Wang, I.C.; Luo, Y.P.; Ting, P.C.; Lin, J.H.; Chang, J.C. Berberine protects cardiac cells against ferroptosis. Tzu Chi. Med. J., 2022, 34(3), 310-317.
[http://dx.doi.org/10.4103/tcmj.tcmj_236_21]

Song, C.; Li, D.; Zhang, J.; Zhao, X. Berberine hydrochloride alleviates imatinib mesylate - induced cardiotoxicity through the inhibition of Nrf2-dependent ferroptosis. Food Funct., 2023, 14(2), 1087-1098.
[http://dx.doi.org/10.1039/D2FO03331C]

Wang, W.; Zhong, X.; Fang, Z.; Li, J.; Li, H.; Liu, X.; Yuan, X.; Huang, W.; Huang, Z. Cardiac sirtuin1 deficiency exacerbates ferroptosis in doxorubicin-induced cardiac injury through the Nrf2/Keap1 pathway. Chem. Biol. Interact., 2023, 2023, 110469.
[http://dx.doi.org/10.1016/j.cbi.2023.110469]

Yu, Y.; Wu, T.; Lu, Y.; Zhao, W; Zhang, J.; Chen, Q.; Ge, G.; Hua, Y.; Chen, K.; Ullah, I.; Zhang, F. Exosomal thioredoxin-1 from hypoxic human umbilical cord mesenchymal stem cells inhibits ferroptosis in doxorubicin-induced cardiotoxicity via mTORC1 signaling. Free Radic. Biol. Med., 2022, 193(Pt 1), 108-121.
[http://dx.doi.org/10.1016/j.freeradbiomed.2022.10.268]

Warpechowski, P.; dos Santos, A.T.L.; Pereira, P.J.I.; de Lima, G.G. Effects of propofol on the cardiac conduction system. Rev. Bras. Anestesiol., 2010, 60(4), 438-444.
[http://dx.doi.org/10.1016/S0034-7094(10)70054-4] [PMID: 20659617]

Barajas, M.B.; Wang, A.; Griffiths, K.K.; Sun, L.; Yang, G.; Levy, R.J. Modeling propofol-induced cardiotoxicity in the isolated-perfused newborn mouse heart. Physiol. Rep., 2022, 10(15), e15402.
[http://dx.doi.org/10.14814/phy2.15402] [PMID: 35923108]

Lu, Z.; Liu, Z.; Fang, B. Propofol protects cardiomyocytes from doxorubicin-induced toxic injury by activating the nuclear factor erythroid 2-related factor 2/glutathione peroxidase 4 signaling pathways. Bioengineered., 2022, 13(4), 9145-9155.
[http://dx.doi.org/10.1080/21655979.2022.2036895]

Li, D.; Liu, X.; Pi, W.; Zhang, Y.; Yu, L.; Xu, C.; Sun, Z.; Jiang, J. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through SIRT1/Nrf2 signaling pathway activation. Front Pharmacol., 2022, 12, 808480.
[http://dx.doi.org/10.3389/fphar.2021.808480]

Ma, T.; Kandhare, A.D.; Mukherjee-Kandhare, A.A.; Bodhankar, S.L. Fisetin, a plant flavonoid ameliorates doxorubicin-induced cardiotoxicity in experimental rats: the decisive role of caspase-3, COX-II, cTn-I, iNOs and TNF-α. Mol Biol Rep., 2019, 46(1), 105-118.
[http://dx.doi.org/10.1007/s11033-018-4450-y]

Zhang, H.; Shen, W.; Gao, C.; Deng, L.; Shen, D. Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer. Drugs R D., 2012, 12(2), 101-106.
[http://dx.doi.org/10.2165/11632530-000000000-00000] [PMID: 22770377]

Wang, X.L.; Wang, X.; Xiong, L.L.; Zhu, Y.; Chen, H.L.; Chen, J.X.; Wang, X.X.; Li, R.L.; Guo, Z.Y.; Li, P.; Jiang, W. Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. J. Cardiovasc. Pharmacol., 2013, 62(6), 512-523.
[http://dx.doi.org/10.1097/FJC.0000000000000009]

Yan, F.; Liu, R.; Zhuang, X.; Li, R.; Shi, H.; Gao, X. Salidroside attenuates doxorubicin-induced cardiac dysfunction partially through activation of QKI/FoxO1 pathway. J. Cardiovasc. Transl. Res., 2021, 14(2), 355-364.
[http://dx.doi.org/10.1007/s12265-020-10056-x]

Chen, H.; Zhu, J.; Le, Y.; Pan, J.; Liu, Y.; Wang, C.; Dou, X.; Lu, D. Salidroside inhibits doxorubicin-induced cardiomyopathy by modulating a ferroptosis-dependent pathway. Phytomedicine., 2022, 99, 153964.
[http://dx.doi.org/10.1016/j.phymed.2022.153964]

Zhang, Y.; Wang, Y.; Xu, J.; Tian, F.; Hu, S.; Chen, Y.; Fu, Z. Melatonin attenuates myocardial ischemia-reperfusion injury via improving mitochondrial fusion/mitophagy and activating the AMPK-OPA1 signaling pathways. J. Pineal Res., 2019, 66(2), e12542.
[http://dx.doi.org/10.1111/jpi.12542] [PMID: 30516280]

Yu, L.M.; Dong, X.; Xue, X.D.; Xu, S.; Zhang, X.; Xu, Y.L.; Wang, Z.S.; Wang, Y.; Gao, H.; Liang, Y.X.; Yang, Y.; Wang, H.S. Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia-reperfusion injury by improving mitochondrial quality control: Role of SIRT6. J. Pineal Res., 2021, 70(1), e12698.
[http://dx.doi.org/10.1111/jpi.12698] [PMID: 33016468]

Zhai, M.; Li, B.; Duan, W.; Jing, L.; Zhang, B.; Zhang, M.; Yu, L.; Liu, Z.; Yu, B.; Ren, K.; Gao, E.; Yang, Y.; Liang, H.; Jin, Z.; Yu, S. Melatonin ameliorates myocardial ischemia reperfusion injury through SIRT3-dependent regulation of oxidative stress and apoptosis. J. Pineal Res., 2017, 63(2), e12419.
[http://dx.doi.org/10.1111/jpi.12419] [PMID: 28500761]

Liu, D.; Ma, Z.; Di, S.; Yang, Y.; Yang, J.; Xu, L.; Reiter, R.J.; Qiao, S.; Yuan, J. AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis. Free Radic. Biol. Med., 2022, 129, 59-72.
[http://dx.doi.org/10.1016/j.freeradbiomed.2018.08.032]

Sun, X.; Sun, P.; Zhen, D.; Xu, X.; Yang, J.; Yang, L.; Fu, D.; Wei, D.; Niu, X.; Tian, J.; Li, H. Melatonin alleviates doxorubicin-induced mitochondrial oxidative damage and ferroptosis in cardiomyocytes by regulating YAP expression. Toxicol. Appl. Pharmacol., 2022, 437, 115902.
[http://dx.doi.org/10.1016/j.taap.2022.115902]

Hanna, M.; Seddiek, H.; Aboulhoda, B.E.; Morcos, G.N.B.; Akabawy, A.M.A.; Elbaset, M.A.; Ibrahim, A.A.; Khalifa, M.M.; Khalifah, I.M.; Fadel, M.S.; Shoukry, T. Synergistic cardioprotective effects of melatonin and deferoxamine through the improvement of ferritinophagy in doxorubicin-induced acute cardiotoxicity. Front. Physiol., 2022, 13, 1050598.
[http://dx.doi.org/10.3389/fphys.2022.1050598] [PMID: 36531171]

Yao, Y.F.; Liu, X.; Li, W.J.; Shi, Z.W.; Yan, Y.X.; Wang, L.F.; Chen, M.; Xie, M.Y. (−)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice. Life Sci., 2017, 180, 151-159.
[http://dx.doi.org/10.1016/j.lfs.2016.12.004] [PMID: 27956351]

Sun, T.L.; Liu, Z.; Qi, Z.J.; Huang, Y.P.; Gao, X.Q.; Zhang, Y.Y. (-)-Epigallocatechin-3-gallate (EGCG) attenuates arsenic-induced cardiotoxicity in rats. Food Chem. Toxicol., 2016, 93, 102-110.
[http://dx.doi.org/10.1016/j.fct.2016.05.004] [PMID: 27170490]

Saeed, N.M.; El-Naga, R.N.; El-Bakly, W.M.; Abdel-Rahman, H.M.; Salah ElDin, R.A.; El-Demerdash, E. Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: A mechanistic study. Biochem. Pharmacol., 2015, 95(3), 145-155.
[http://dx.doi.org/10.1016/j.bcp.2015.02.006] [PMID: 25701654]

Li, W.; Nie, S.; Xie, M.; Chen, Y.; Li, C.; Zhang, H. A major green tea component, (-)-epigallocatechin-3-gallate, ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. J. Agric. Food Chem., 2010, 58(16), 8977-8982.
[http://dx.doi.org/10.1021/jf101277t] [PMID: 20666448]

He, H.; Wang, L.; Qiao, Y.; Yang, B.; Yin, D.; He, M. Epigallocatechin-3-gallate pretreatment alleviates doxorubicin-induced ferroptosis and cardiotoxicity by upregulating AMPKα2 and activating adaptive autophagy. Redox Biol., 2021, 48, 102185.
[http://dx.doi.org/10.1016/j.redox.2021.102185]

Quagliariello, V.; De Laurentiis, M.; Rea, D.; Barbieri, A.; Monti, M.G.; Carbone, A.; Paccone, A.; Altucci, L.; Conte, M.; Canale, M.L.; Botti, G.; Maurea, N. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc. Diabetol., 2021, 20(1), 150.
[http://dx.doi.org/10.1186/s12933-021-01346-y]

Min, J.; Wu, L.; Liu, Y.; Song, G.; Deng, Q.; Jin, W.; Yu, W.; Abudureyimu, M.; Pei, Z.; Ren, J. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci., 2022, 312, 121207.
[http://dx.doi.org/10.1016/j.lfs.2022.121207]

Sabatino, J.; De Rosa, S.; Tammè, L.; Iaconetti, C.; Sorrentino, S.; Polimeni, A.; Mignogna, C.; Amorosi, A.; Spaccarotella, C.; Yasuda, M.; Indolfi, C. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc. Diabetol., 2020, 19(1), 66.
[http://dx.doi.org/10.1186/s12933-020-01040-5] [PMID: 32414364]

Barış, V.Ö.; Dinçsoy, A.B.; Gedikli, E.; Zırh, S.; Müftüoğlu, S.; Erdem, A. Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways. Cardiovasc. Toxicol., 2021, 21(9), 747-758.
[http://dx.doi.org/10.1007/s12012-021-09665-y] [PMID: 34089496]

Eliaa, S.G.; Al-Karmalawy, A.A.; Saleh, R.M.; Elshal, M.F. Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mtor pathway and inhibition of calmodulin: In vitro and molecular docking studies. ACS Pharmacol. Transl. Sci., 2020, 3(6), 1330-1338.
[http://dx.doi.org/10.1021/acsptsci.0c00144] [PMID: 33344906]

Ren, C.; Sun, K.; Zhang, Y.; Hu, Y.; Hu, B.; Zhao, J.; He, Z.; Ding, R.; Wang, W.; Liang, C. Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. Front Pharmacol., 2021, 12, 664181.
[http://dx.doi.org/10.3389/fphar.2021.664181]

Martín-Garcia, A.; López-Fernández, T.; Mitroi, C.; Chaparro-Muñoz, M.; Moliner, P.; Martin-Garcia, A.C.; Martinez-Monzonis, A.; Castro, A.; Lopez-Sendon, J.L.; Sanchez, P.L. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. ESC Heart Fail., 2020, 7(2), 763-767.
[http://dx.doi.org/10.1002/ehf2.12627]

Miyoshi, T.; Nakamura, K.; Amioka, N.; Hatipoglu, O.F.; Yonezawa, T.; Saito, Y.; Yoshida, M.; Akagi, S.; Ito, H. LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats. Sci. Rep., 2022, 12(1), 4930.
[http://dx.doi.org/10.1038/s41598-022-09094-z] [PMID: 35322164]

Xia, Y.; Chen, Z.; Chen, A.; Fu, M.; Dong, Z.; Hu, K.; Yang, X.; Zou, Y.; Sun, A.; Qian, J.; Ge, J. LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J. Mol. Cell. Cardiol., 2017, 108, 138-148.
[http://dx.doi.org/10.1016/j.yjmcc.2017.06.003] [PMID: 28623750]

Sobiborowicz-Sadowska, A.M.; Kamińska, K.; Cudnoch-Jędrzejewska, A. Neprilysin inhibition in the prevention of anthracycline-induced cardiotoxicity. Cancers (Basel), 2023, 15(1), 312.
[http://dx.doi.org/10.3390/cancers15010312] [PMID: 36612307]

Dankowski, R.; Sacharczuk, W.; Łojko-Dankowska, A.; Nowicka, A.; Szałek-Goralewska, A.; Szyszka, A. Sacubitril/valsartan as first-line therapy in anthracycline-induced cardiotoxicity. Kardiol. Pol., 2021, 79(9), 1040-1041.
[http://dx.doi.org/10.33963/KP.a2021.0052] [PMID: 34227674]

Sheppard, C.E.; Anwar, M. The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series. J. Oncol. Pharm. Pract., 2019, 25(5), 1231-1234.
[http://dx.doi.org/10.1177/1078155218783238] [PMID: 29945530]

Wu, Z.; Chen, H.; Lin, L.; Lu, J.; Zhao, Q.; Dong, Z.; Hai, X. Sacubitril/valsartan protects against arsenic trioxide induced cardiotoxicity in vivo and in vitro. Toxicol. Res., 2022, 11(3), 451-459.
[http://dx.doi.org/10.1093/toxres/tfac018] [PMID: 35782642]

Liu, X.; Li, D.; Pi, W.; Wang, B.; Xu, S.; Yu, L.; Yao, L.; Sun, Z.; Jiang, J.; Mi, Y. LCZ696 protects against doxorubicin-induced cardiotoxicity by inhibiting ferroptosis via AKT/SIRT3/SOD2 signaling pathway activation. Int. Immunopharmacol., 2022, 113(Pt A), 109379.
[http://dx.doi.org/10.1016/j.intimp.2022.109379]

Abe, K.; Ikeda, M.; Ide, T.; Tadokoro, T.; Miyamoto, H.D.; Furusawa, S.; Tsutsui, Y.; Miyake, R.; Ishimaru, K.; Watanabe, M.; Matsushima, S.; Koumura, T.; Yamada, K.I.; Imai, H.; Tsutsui, H. Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis. Sci. Signal., 2022, 15(758), eabn8017.
[http://dx.doi.org/10.1126/scisignal.abn8017]

Pinelli, A.; Trivulzio, S.; Brenna, S.; Rossoni, G. Plasma cardiac necrosis markers C-troponin I and creatine kinase, associated with increased malondialdehyde levels, induced in rabbits by means of 5-aminolevulinic acid injection. Pharmacology., 2019, 84(5), 314-321.
[http://dx.doi.org/10.1159/000248216]

Liberale, L.; Bonaventura, A.; Montecucco, F.; Dallegri, F.; Carbone, F. Impact of red wine consumption on cardiovascular health. Curr. Med. Chem., 2019, 26(19), 3542-3566.
[http://dx.doi.org/10.2174/0929867324666170518100606]

Zaffaroni, N.; Beretta, G.L. Resveratrol and prostate cancer: The power of phytochemicals. Curr. Med. Chem., 2021, 28(24), 4845-4862.
[http://dx.doi.org/10.2174/1875533XMTEyhNzIfw] [PMID: 33371831]

Zeng, Y.; Cao, G.; Lin, L.; Zhang, Y.; Luo, X.; Ma, X.; Aiyisake, A.; Cheng, Q. Resveratrol attenuates sepsis-induced cardiomyopathy in rats through anti-ferroptosis via the Sirt1/Nrf2 pathway. J. Invest. Surg., 2023, 36(1), 2157521.
[http://dx.doi.org/10.1080/08941939.2022.2157521] [PMID: 36576230]

Yu, W.; Chen, C.; Xu, C.; Xie, D.; Wang, Q.; Liu, W.; Zhao, H.; He, F.; Chen, B.; Xi, Y.; Yan, Y.; Yu, L.; Cheng, J. Activation of p62-NRF2 axis protects against doxorubicin-induced ferroptosis in cardiomyocytes: A novel role and molecular mechanism of resveratrol. Am. J. Chin. Med., 2022, 50(8), 2103-2123.
[http://dx.doi.org/10.1142/S0192415X22500902]

Li, D.; Song, C.; Zhang, J.; Zhao, X. Resveratrol alleviated 5-FU-induced cardiotoxicity by attenuating GPX4 dependent ferroptosis. J. Nutr. Biochem., 2023, 112, 109241.
[http://dx.doi.org/10.1016/j.jnutbio.2022.109241]

Tadokoro, T.; Ikeda, M.; Abe, K.; Ide, T.; Miyamoto, H.D.; Furusawa, S.; Ishimaru, K.; Watanabe, M.; Ishikita, A.; Matsushima, S.; Koumura, T.; Yamada, K.I.; Imai, H.; Tsutsui, H. Ethoxyquin is a competent radical-trapping antioxidant for preventing ferroptosis in doxorubicin cardiotoxicity. J. Cardiovasc. Pharmacol., 2022, 80(5), 690-699.
[http://dx.doi.org/10.1097/FJC.0000000000001328]

Tang, X.G.; Lin, K.; Guo, S.W.; Rong, Y.; Chen, D.; Chen, Z.S.; Ping, F.F.; Wang, J.Q. The synergistic effect of ruthenium complex ∆-Ru1 and doxorubicin in a mouse breast cancer model. Recent Pat. Anticancer Drug Discov., 2022, 18(2), 174-186.
[http://dx.doi.org/10.2174/1574892817666220629105543]